Health Canada Approves Ropeginterferon Alfa-2b for Polycythemia Vera
Health Canada has approved ropeginterferon alfa-2b for the treatment of polycythemia vera (PV), a rare blood cancer. This regulatory milestone allows patients in Canada access to a long-acting interferon designed ... Read More